**Supplementary Table 3. Demographics, Disease Characteristics, and Medical History at Baseline for Patients Enrolled in EAMS Who Consented to EQ-5D-3L Completion and Returned a Questionnaire**

|  | **Patients Enrolled in EAMS who Consented to EQ-5D-3L Completion and Returned a Questionnaire**  **(N=71)a** |
| --- | --- |
| **Age at baseline, years** | **N=71** |
| Median | 63 |
| Range | 32–87 |
| **Gender, n (%)** | **N=71** |
| Male | 55 (77.5) |
| Female | 16 (22.5) |
| **Race, n (%)** | **N=70** |
| White | 66 (94.3) |
| Asian (Indian, Pakistani, Bangladeshi) | 1 (1.4) |
| Asian (Chinese, Japanese, Korean, Taiwanese) | 1 (1.4) |
| Other | 2 (2.9) |
| **Number of prior or pre-existing comorbidities at therapy initiation, n (%)** | **N=70** |
| 0 | 31 (44.3) |
| 1 | 21 (30.0) |
| 2 | 8 (11.4) |
| 3 or more | 10 (14.3) |
| **Most common prior or pre-existing comorbidities at therapy initiationb, n (%)** | **N=70** |
| Hypertension | 11 (15.7) |
| ‘Other’ cardiovascular | 9 (12.9) |
| **Concomitant medications, n (%)** | **N=70** |
| Yes | 60 (85.7) |
| No | 10 (14.3) |
| **Most common types of concomitant medicationsb, n (%)** | **N=70** |
| Proton pump inhibitors | 45 (64.3) |
| Opioid analgesics | 21 (30.0) |
| Antiemetic drugs | 13 (18.6) |
| Non-opioid analgesics | 15 (21.4) |
| Antithrombotic drugs | 10 (14.3) |
| **Primary tumour location, n (%)** | **N-71** |
| Gastric adenocarcinoma | 25 (35.2) |
| Gastroesophageal junction | 46 (64.8) |
| **Tumour histology (adenocarcinoma), n (%)** | **N=71** |
| Yes | 71 (100.0) |
| **Number of organs with metastases, n (%)** | **N=71** |
| ≤1 | 29 (40.8) |
| ≥2 | 42 (59.2) |
| **Sites of metastasesc, n (%)** | **N=70** |
| Lymph node | 49 (70.0) |
| Liver | 26 (37.1) |
| Lung | 17 (24.3) |
| Peritoneum | 18 (25.7) |
| Bone | 7 (10.0) |
| Other | 6 (8.6) |
| **ECOG performance status, n (%)** | **N=71** |
| 0 | 13 (18.3) |
| 1 | 54 (76.1) |
| 2 | 4 (5.6) |
| **Number of prior systemic treatments for advanced gastric or GEJ cancer, n (%)** | **N=69** |
| 2 | 61 (88.4) |
| 3 | 8 (11.6) |
| **Prior surgery for gastric or GEJ cancer, n (%)** | **N=69** |
| Yes | 22 (31.9) |
| No | 47 (68.1) |

a For one patient, the identification number was missing, and the EQ-5D questionnaire data could not be matched with the baseline data

b ‘Most common’ reported comorbidities and concomitant medications are those that were reported in at least 10% of patients who consented to observational research. More than one comorbidity or concomitant medication may have been reported per patient

c More than one site may have been reported per patient.

Abbreviations: EAMS = Early Access to Medicines Scheme; ECOG = Eastern Cooperative Oncology Group; EQ-5D-3L = EuroQoL Five Dimensions, Three Levels questionnaire; GEJ = gastroesophageal junction